Form 4 Filing for Contineum Therapeutics, Inc.

This filing details Form 4 transactions for Contineum Therapeutics, Inc. (CTNM) on May 1, 2026. Lorrain Daniel S., Chief Scientific Officer, reported the sale of 3,870 shares of Class A Common Stock at a weighted average price of $13.06, with individual sales ranging from $12.69 to $13.57. An additional 300 shares of Class A Common Stock were sold at a weighted average price of $13.84, with prices ranging from $13.79 to $13.86. These sales were conducted under a 10b5-1 trading plan. Following these transactions, the reporting person directly owns 143,542 shares, and indirectly owns 6,842 shares through their spouse.